{"metadata":{"language_info":{"name":"python","version":"3.7.8","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"},"kernelspec":{"name":"python3","display_name":"Python 3","language":"python"}},"nbformat_minor":5,"nbformat":4,"cells":[{"cell_type":"code","source":"import pandas as pd\nimport numpy as np\nfrom sklearn.preprocessing import MinMaxScaler\nimport matplotlib.pyplot as plt\nfrom sklearn.model_selection import train_test_split\nfrom sklearn.linear_model import LinearRegression\nfrom sklearn.metrics import mean_absolute_error, mean_squared_error, median_absolute_error, r2_score\nfrom sklearn import tree\nimport re","metadata":{"trusted":true},"execution_count":59,"outputs":[]},{"cell_type":"code","source":"def load_data():\n    '''\n    Загрузка данных\n    '''\n    data = pd.read_csv('health_unit_district_wise_covid_19_vaccination_in_tamilnadu_as_on_30_05_2021.csv')\n    return data\n\n\ndef preprocess_data(data_in):\n    '''\n    Масштабирование признаков, функция возвращает X и y для кросс-валидации\n    '''\n    data_out = data_in.copy()\n    # Числовые колонки для масштабирования\n    scale_cols = ['Session planned for Covishield', 'Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group']\n    new_cols = []\n    sc1 = MinMaxScaler()\n    sc1_data = sc1.fit_transform(data_out[scale_cols])\n    for i in range(len(scale_cols)):\n        col = scale_cols[i]\n        new_col_name = col + '_scaled'\n        new_cols.append(new_col_name)\n        data_out[new_col_name] = sc1_data[:, i]\n    X = data_out[new_cols]\n    Y = data_out['Session held for Covishield']\n    X_train, X_test, y_train, y_test = train_test_split(X, Y, train_size=0.8, test_size=0.2, random_state=1)\n    return X_train, X_test, y_train, y_test, X, Y\n\n\ndata = load_data()","metadata":{"trusted":true},"execution_count":60,"outputs":[]},{"cell_type":"code","source":"data.head()","metadata":{"trusted":true},"execution_count":61,"outputs":[{"execution_count":61,"output_type":"execute_result","data":{"text/plain":"   S.No Health Unit District  Session planned for Covishield  \\\n0     1           Aranthangi                              41   \n1     2             Ariyalur                              66   \n2     3                Attur                              51   \n3     4           Chengalpet                              30   \n4     5              Chennai                              90   \n\n   Session held for Covishield  \\\n0                           41   \n1                           66   \n2                           51   \n3                           30   \n4                           90   \n\n   Achievement towards vaccination of 1st Dosage Covishield to HCW  \\\n0                                                  0                 \n1                                                 15                 \n2                                                  0                 \n3                                                 10                 \n4                                                 27                 \n\n   Achievement towards vaccination of 2nd Dosage Covishield to HCW  \\\n0                                                  2                 \n1                                                  7                 \n2                                                  0                 \n3                                                  0                 \n4                                                  3                 \n\n   Achievement towards vaccination of 1st Dosage Covishield to FLW  \\\n0                                                  2                 \n1                                                  5                 \n2                                                  0                 \n3                                                  1                 \n4                                                110                 \n\n   Achievement towards vaccination of 2nd Dosage Covishield to FLW  \\\n0                                                  5                 \n1                                                 10                 \n2                                                  0                 \n3                                                  0                 \n4                                                  7                 \n\n   Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group  \\\n0                                                 36                                                                        \n1                                                585                                                                        \n2                                                  0                                                                        \n3                                                346                                                                        \n4                                               2042                                                                        \n\n   Achievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 18 years and less than 44 years age group  \\\n0                                                  0                                                                        \n1                                                  0                                                                        \n2                                                  0                                                                        \n3                                                  0                                                                        \n4                                                  0                                                                        \n\n   ...  \\\n0  ...   \n1  ...   \n2  ...   \n3  ...   \n4  ...   \n\n   Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to FLW  \\\n0                                                  9                                   \n1                                                 10                                   \n2                                                  0                                   \n3                                                  4                                   \n4                                                 47                                   \n\n   Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group  \\\n0                                                 59                                                                                          \n1                                                625                                                                                          \n2                                                  0                                                                                          \n3                                               1180                                                                                          \n4                                               3993                                                                                          \n\n   Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group  \\\n0                                                  0                                                                                          \n1                                                  0                                                                                          \n2                                                  0                                                                                          \n3                                                  0                                                                                          \n4                                                  0                                                                                          \n\n   Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities  \\\n0                                                 47                                                                                                             \n1                                                281                                                                                                             \n2                                                  6                                                                                                             \n3                                                553                                                                                                             \n4                                               2270                                                                                                             \n\n   Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities  \\\n0                                                 24                                                                                                             \n1                                                 17                                                                                                             \n2                                                  4                                                                                                             \n3                                                 36                                                                                                             \n4                                                405                                                                                                             \n\n   Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities  \\\n0                                                 17                                                                          \n1                                                 32                                                                          \n2                                                  0                                                                          \n3                                                259                                                                          \n4                                                726                                                                          \n\n   Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities  \\\n0                                                  6                                                                          \n1                                                  8                                                                          \n2                                                  0                                                                          \n3                                                 21                                                                          \n4                                                125                                                                          \n\n   Total Achievement towards vaccination to beneficiaries under 1st Dose of Covishield and Covaxin  \\\n0                                                126                                                 \n1                                                958                                                 \n2                                                  6                                                 \n3                                               2003                                                 \n4                                               7179                                                 \n\n   Total Achievement towards vaccination to beneficiaries under 2nd Dose of Covishield and Covaxin  \\\n0                                                 43                                                 \n1                                                 42                                                 \n2                                                  4                                                 \n3                                                 61                                                 \n4                                                655                                                 \n\n   Total Achievement towards vaccination of Covishield and Covaxin (1st and 2nd Dose)  \n0                                                169                                   \n1                                               1000                                   \n2                                                 10                                   \n3                                               2064                                   \n4                                               7834                                   \n\n[5 rows x 45 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>S.No</th>\n      <th>Health Unit District</th>\n      <th>Session planned for Covishield</th>\n      <th>Session held for Covishield</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to HCW</th>\n      <th>Achievement towards vaccination of 2nd Dosage Covishield to HCW</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to FLW</th>\n      <th>Achievement towards vaccination of 2nd Dosage Covishield to FLW</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Achievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>...</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to FLW</th>\n      <th>Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities</th>\n      <th>Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities</th>\n      <th>Total Achievement towards vaccination to beneficiaries under 1st Dose of Covishield and Covaxin</th>\n      <th>Total Achievement towards vaccination to beneficiaries under 2nd Dose of Covishield and Covaxin</th>\n      <th>Total Achievement towards vaccination of Covishield and Covaxin (1st and 2nd Dose)</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>1</td>\n      <td>Aranthangi</td>\n      <td>41</td>\n      <td>41</td>\n      <td>0</td>\n      <td>2</td>\n      <td>2</td>\n      <td>5</td>\n      <td>36</td>\n      <td>0</td>\n      <td>...</td>\n      <td>9</td>\n      <td>59</td>\n      <td>0</td>\n      <td>47</td>\n      <td>24</td>\n      <td>17</td>\n      <td>6</td>\n      <td>126</td>\n      <td>43</td>\n      <td>169</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>2</td>\n      <td>Ariyalur</td>\n      <td>66</td>\n      <td>66</td>\n      <td>15</td>\n      <td>7</td>\n      <td>5</td>\n      <td>10</td>\n      <td>585</td>\n      <td>0</td>\n      <td>...</td>\n      <td>10</td>\n      <td>625</td>\n      <td>0</td>\n      <td>281</td>\n      <td>17</td>\n      <td>32</td>\n      <td>8</td>\n      <td>958</td>\n      <td>42</td>\n      <td>1000</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>3</td>\n      <td>Attur</td>\n      <td>51</td>\n      <td>51</td>\n      <td>0</td>\n      <td>0</td>\n      <td>0</td>\n      <td>0</td>\n      <td>0</td>\n      <td>0</td>\n      <td>...</td>\n      <td>0</td>\n      <td>0</td>\n      <td>0</td>\n      <td>6</td>\n      <td>4</td>\n      <td>0</td>\n      <td>0</td>\n      <td>6</td>\n      <td>4</td>\n      <td>10</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>4</td>\n      <td>Chengalpet</td>\n      <td>30</td>\n      <td>30</td>\n      <td>10</td>\n      <td>0</td>\n      <td>1</td>\n      <td>0</td>\n      <td>346</td>\n      <td>0</td>\n      <td>...</td>\n      <td>4</td>\n      <td>1180</td>\n      <td>0</td>\n      <td>553</td>\n      <td>36</td>\n      <td>259</td>\n      <td>21</td>\n      <td>2003</td>\n      <td>61</td>\n      <td>2064</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>5</td>\n      <td>Chennai</td>\n      <td>90</td>\n      <td>90</td>\n      <td>27</td>\n      <td>3</td>\n      <td>110</td>\n      <td>7</td>\n      <td>2042</td>\n      <td>0</td>\n      <td>...</td>\n      <td>47</td>\n      <td>3993</td>\n      <td>0</td>\n      <td>2270</td>\n      <td>405</td>\n      <td>726</td>\n      <td>125</td>\n      <td>7179</td>\n      <td>655</td>\n      <td>7834</td>\n    </tr>\n  </tbody>\n</table>\n<p>5 rows × 45 columns</p>\n</div>"},"metadata":{}}]},{"cell_type":"code","source":"data.shape","metadata":{"trusted":true},"execution_count":62,"outputs":[{"execution_count":62,"output_type":"execute_result","data":{"text/plain":"(45, 45)"},"metadata":{}}]},{"cell_type":"code","source":"data.isnull().sum()","metadata":{"trusted":true},"execution_count":63,"outputs":[{"execution_count":63,"output_type":"execute_result","data":{"text/plain":"S.No                                                                                                                                                           0\nHealth Unit District                                                                                                                                           0\nSession planned for Covishield                                                                                                                                 0\nSession held for Covishield                                                                                                                                    0\nAchievement towards vaccination of 1st Dosage Covishield to HCW                                                                                                0\nAchievement towards vaccination of 2nd Dosage Covishield to HCW                                                                                                0\nAchievement towards vaccination of 1st Dosage Covishield to FLW                                                                                                0\nAchievement towards vaccination of 2nd Dosage Covishield to FLW                                                                                                0\nAchievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group                                         0\nAchievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 18 years and less than 44 years age group                                         0\nAchievement towards vaccination of 1st Dosage Covishield to beneficiaries of 45 years and less than 60 years age group with Comorbidities                      0\nAchievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 45 years and less than 60 years age group with Comorbidities                      0\nAchievement towards vaccination of 1st Dosage Covishield to 60+ years beneficiaries with Comorbidities                                                         0\nAchievement towards vaccination of 2nd Dosage Covishield to 60+ years beneficiaries with Comorbidities                                                         0\nTotal Achievement of vaccination to beneficiaries under 1st Dose of Covishield                                                                                 0\nTotal Achievement of vaccination to beneficiaries under 2nd Dose of Covishield                                                                                 0\nSession planned for Covaxin                                                                                                                                    0\nSession held for Covaxin                                                                                                                                       0\nAchievement towards vaccination of 1st Dosage Covaxin to HCW                                                                                                   0\nAchievement towards vaccination of 2nd Dosage Covaxin to HCW                                                                                                   0\nAchievement towards vaccination of 1st Dosage Covaxin to FLW                                                                                                   0\nAchievement towards vaccination of 2nd Dosage Covaxin to FLW                                                                                                   0\nAchievement towards vaccination of 1st Dosage Covaxin to beneficiaries of 18 years and less than 44 years age group                                            0\nAchievement towards vaccination of 2nd Dosage Covaxin to beneficiaries of 18 years and less than 44 years age group                                            0\nAchievement towards vaccination of 1st Dosage Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities                         0\nAchievement towards vaccination of 2nd Dosage Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities                         0\nAchievement towards vaccination of 1st Dosage Covaxin to 60+ years beneficiaries with Comorbidities                                                            0\nAchievement towards vaccination of 2nd Dosage Covaxin to 60+ years beneficiaries with Comorbidities                                                            0\nTotal Achievement of vaccination to beneficiaries under 1st Dose of Covaxin                                                                                    0\nTotal Achievement of vaccination to beneficiaries under 2nd Dose of Covaxin                                                                                    0\nTotal Session planned for Covishield and Covaxin                                                                                                               0\nTotal Session held for Covishield and Covaxin                                                                                                                  0\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to HCW                                                                              0\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to HCW                                                                              0\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to FLW                                                                              0\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to FLW                                                                              0\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group                       0\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group                       0\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities    0\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities    0\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities                                       0\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities                                       0\nTotal Achievement towards vaccination to beneficiaries under 1st Dose of Covishield and Covaxin                                                                0\nTotal Achievement towards vaccination to beneficiaries under 2nd Dose of Covishield and Covaxin                                                                0\nTotal Achievement towards vaccination of Covishield and Covaxin (1st and 2nd Dose)                                                                             0\ndtype: int64"},"metadata":{}}]},{"cell_type":"code","source":"data.dtypes","metadata":{"trusted":true},"execution_count":64,"outputs":[{"execution_count":64,"output_type":"execute_result","data":{"text/plain":"S.No                                                                                                                                                            int64\nHealth Unit District                                                                                                                                           object\nSession planned for Covishield                                                                                                                                  int64\nSession held for Covishield                                                                                                                                     int64\nAchievement towards vaccination of 1st Dosage Covishield to HCW                                                                                                 int64\nAchievement towards vaccination of 2nd Dosage Covishield to HCW                                                                                                 int64\nAchievement towards vaccination of 1st Dosage Covishield to FLW                                                                                                 int64\nAchievement towards vaccination of 2nd Dosage Covishield to FLW                                                                                                 int64\nAchievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group                                          int64\nAchievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 18 years and less than 44 years age group                                          int64\nAchievement towards vaccination of 1st Dosage Covishield to beneficiaries of 45 years and less than 60 years age group with Comorbidities                       int64\nAchievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 45 years and less than 60 years age group with Comorbidities                       int64\nAchievement towards vaccination of 1st Dosage Covishield to 60+ years beneficiaries with Comorbidities                                                          int64\nAchievement towards vaccination of 2nd Dosage Covishield to 60+ years beneficiaries with Comorbidities                                                          int64\nTotal Achievement of vaccination to beneficiaries under 1st Dose of Covishield                                                                                  int64\nTotal Achievement of vaccination to beneficiaries under 2nd Dose of Covishield                                                                                  int64\nSession planned for Covaxin                                                                                                                                     int64\nSession held for Covaxin                                                                                                                                        int64\nAchievement towards vaccination of 1st Dosage Covaxin to HCW                                                                                                    int64\nAchievement towards vaccination of 2nd Dosage Covaxin to HCW                                                                                                    int64\nAchievement towards vaccination of 1st Dosage Covaxin to FLW                                                                                                    int64\nAchievement towards vaccination of 2nd Dosage Covaxin to FLW                                                                                                    int64\nAchievement towards vaccination of 1st Dosage Covaxin to beneficiaries of 18 years and less than 44 years age group                                             int64\nAchievement towards vaccination of 2nd Dosage Covaxin to beneficiaries of 18 years and less than 44 years age group                                             int64\nAchievement towards vaccination of 1st Dosage Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities                          int64\nAchievement towards vaccination of 2nd Dosage Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities                          int64\nAchievement towards vaccination of 1st Dosage Covaxin to 60+ years beneficiaries with Comorbidities                                                             int64\nAchievement towards vaccination of 2nd Dosage Covaxin to 60+ years beneficiaries with Comorbidities                                                             int64\nTotal Achievement of vaccination to beneficiaries under 1st Dose of Covaxin                                                                                     int64\nTotal Achievement of vaccination to beneficiaries under 2nd Dose of Covaxin                                                                                     int64\nTotal Session planned for Covishield and Covaxin                                                                                                                int64\nTotal Session held for Covishield and Covaxin                                                                                                                   int64\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to HCW                                                                               int64\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to HCW                                                                               int64\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to FLW                                                                               int64\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to FLW                                                                               int64\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group                        int64\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group                        int64\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities     int64\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities     int64\nTotal Achievement towards vaccination of 1st Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities                                        int64\nTotal Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities                                        int64\nTotal Achievement towards vaccination to beneficiaries under 1st Dose of Covishield and Covaxin                                                                 int64\nTotal Achievement towards vaccination to beneficiaries under 2nd Dose of Covishield and Covaxin                                                                 int64\nTotal Achievement towards vaccination of Covishield and Covaxin (1st and 2nd Dose)                                                                              int64\ndtype: object"},"metadata":{}}]},{"cell_type":"code","source":"data.describe()","metadata":{"trusted":true},"execution_count":65,"outputs":[{"execution_count":65,"output_type":"execute_result","data":{"text/plain":"            S.No  Session planned for Covishield  Session held for Covishield  \\\ncount  45.000000                       45.000000                    45.000000   \nmean   23.000000                       45.533333                    44.955556   \nstd    13.133926                       28.664676                    29.017985   \nmin     1.000000                        2.000000                     2.000000   \n25%    12.000000                       24.000000                    20.000000   \n50%    23.000000                       43.000000                    43.000000   \n75%    34.000000                       61.000000                    61.000000   \nmax    45.000000                      105.000000                   105.000000   \n\n       Achievement towards vaccination of 1st Dosage Covishield to HCW  \\\ncount                                          45.000000                 \nmean                                            3.000000                 \nstd                                             9.816498                 \nmin                                             0.000000                 \n25%                                             0.000000                 \n50%                                             0.000000                 \n75%                                             0.000000                 \nmax                                            58.000000                 \n\n       Achievement towards vaccination of 2nd Dosage Covishield to HCW  \\\ncount                                          45.000000                 \nmean                                            1.333333                 \nstd                                             3.636932                 \nmin                                             0.000000                 \n25%                                             0.000000                 \n50%                                             0.000000                 \n75%                                             1.000000                 \nmax                                            20.000000                 \n\n       Achievement towards vaccination of 1st Dosage Covishield to FLW  \\\ncount                                          45.000000                 \nmean                                           23.044444                 \nstd                                            77.816788                 \nmin                                             0.000000                 \n25%                                             0.000000                 \n50%                                             0.000000                 \n75%                                             4.000000                 \nmax                                           415.000000                 \n\n       Achievement towards vaccination of 2nd Dosage Covishield to FLW  \\\ncount                                          45.000000                 \nmean                                            1.222222                 \nstd                                             2.754244                 \nmin                                             0.000000                 \n25%                                             0.000000                 \n50%                                             0.000000                 \n75%                                             0.000000                 \nmax                                            10.000000                 \n\n       Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group  \\\ncount                                          45.000000                                                                        \nmean                                          417.822222                                                                        \nstd                                           493.723344                                                                        \nmin                                             0.000000                                                                        \n25%                                            42.000000                                                                        \n50%                                           230.000000                                                                        \n75%                                           585.000000                                                                        \nmax                                          2042.000000                                                                        \n\n       Achievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 18 years and less than 44 years age group  \\\ncount                                               45.0                                                                        \nmean                                                 0.0                                                                        \nstd                                                  0.0                                                                        \nmin                                                  0.0                                                                        \n25%                                                  0.0                                                                        \n50%                                                  0.0                                                                        \n75%                                                  0.0                                                                        \nmax                                                  0.0                                                                        \n\n       Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 45 years and less than 60 years age group with Comorbidities  \\\ncount                                          45.000000                                                                                           \nmean                                          307.511111                                                                                           \nstd                                           531.891976                                                                                           \nmin                                             0.000000                                                                                           \n25%                                            35.000000                                                                                           \n50%                                           122.000000                                                                                           \n75%                                           315.000000                                                                                           \nmax                                          2828.000000                                                                                           \n\n       ...  \\\ncount  ...   \nmean   ...   \nstd    ...   \nmin    ...   \n25%    ...   \n50%    ...   \n75%    ...   \nmax    ...   \n\n       Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to FLW  \\\ncount                                          45.000000                                   \nmean                                            4.400000                                   \nstd                                             9.656369                                   \nmin                                             0.000000                                   \n25%                                             0.000000                                   \n50%                                             0.000000                                   \n75%                                             4.000000                                   \nmax                                            47.000000                                   \n\n       Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group  \\\ncount                                          45.000000                                                                                          \nmean                                          637.155556                                                                                          \nstd                                           768.935538                                                                                          \nmin                                             0.000000                                                                                          \n25%                                           129.000000                                                                                          \n50%                                           398.000000                                                                                          \n75%                                           981.000000                                                                                          \nmax                                          3993.000000                                                                                          \n\n       Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group  \\\ncount                                               45.0                                                                                          \nmean                                                 0.0                                                                                          \nstd                                                  0.0                                                                                          \nmin                                                  0.0                                                                                          \n25%                                                  0.0                                                                                          \n50%                                                  0.0                                                                                          \n75%                                                  0.0                                                                                          \nmax                                                  0.0                                                                                          \n\n       Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities  \\\ncount                                          45.000000                                                                                                             \nmean                                          331.755556                                                                                                             \nstd                                           568.957706                                                                                                             \nmin                                             0.000000                                                                                                             \n25%                                            53.000000                                                                                                             \n50%                                           124.000000                                                                                                             \n75%                                           344.000000                                                                                                             \nmax                                          3007.000000                                                                                                             \n\n       Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities  \\\ncount                                          45.000000                                                                                                             \nmean                                           55.200000                                                                                                             \nstd                                            80.459363                                                                                                             \nmin                                             0.000000                                                                                                             \n25%                                            14.000000                                                                                                             \n50%                                            30.000000                                                                                                             \n75%                                            63.000000                                                                                                             \nmax                                           405.000000                                                                                                             \n\n       Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities  \\\ncount                                          45.000000                                                                          \nmean                                          109.933333                                                                          \nstd                                           223.154797                                                                          \nmin                                             0.000000                                                                          \n25%                                             7.000000                                                                          \n50%                                            32.000000                                                                          \n75%                                           113.000000                                                                          \nmax                                          1263.000000                                                                          \n\n       Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities  \\\ncount                                          45.000000                                                                          \nmean                                           26.955556                                                                          \nstd                                            42.491687                                                                          \nmin                                             0.000000                                                                          \n25%                                             0.000000                                                                          \n50%                                             8.000000                                                                          \n75%                                            28.000000                                                                          \nmax                                           200.000000                                                                          \n\n       Total Achievement towards vaccination to beneficiaries under 1st Dose of Covishield and Covaxin  \\\ncount                                          45.000000                                                 \nmean                                         1107.222222                                                 \nstd                                          1393.188689                                                 \nmin                                             0.000000                                                 \n25%                                           315.000000                                                 \n50%                                           883.000000                                                 \n75%                                          1321.000000                                                 \nmax                                          7179.000000                                                 \n\n       Total Achievement towards vaccination to beneficiaries under 2nd Dose of Covishield and Covaxin  \\\ncount                                          45.000000                                                 \nmean                                           91.355556                                                 \nstd                                           138.270676                                                 \nmin                                             0.000000                                                 \n25%                                            19.000000                                                 \n50%                                            55.000000                                                 \n75%                                            85.000000                                                 \nmax                                           655.000000                                                 \n\n       Total Achievement towards vaccination of Covishield and Covaxin (1st and 2nd Dose)  \ncount                                          45.000000                                   \nmean                                         1198.577778                                   \nstd                                          1511.056817                                   \nmin                                             0.000000                                   \n25%                                           396.000000                                   \n50%                                           883.000000                                   \n75%                                          1455.000000                                   \nmax                                          7834.000000                                   \n\n[8 rows x 44 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>S.No</th>\n      <th>Session planned for Covishield</th>\n      <th>Session held for Covishield</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to HCW</th>\n      <th>Achievement towards vaccination of 2nd Dosage Covishield to HCW</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to FLW</th>\n      <th>Achievement towards vaccination of 2nd Dosage Covishield to FLW</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Achievement towards vaccination of 2nd Dosage Covishield to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Achievement towards vaccination of 1st Dosage Covishield to beneficiaries of 45 years and less than 60 years age group with Comorbidities</th>\n      <th>...</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to FLW</th>\n      <th>Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 18 years and less than 44 years age group</th>\n      <th>Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to beneficiaries of 45 years and less than 60 years age group with Comorbidities</th>\n      <th>Total Achievement towards vaccination of 1st Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities</th>\n      <th>Total Achievement towards vaccination of 2nd Dosage Covishield and Covaxin to 60+ years beneficiaries with Comorbidities</th>\n      <th>Total Achievement towards vaccination to beneficiaries under 1st Dose of Covishield and Covaxin</th>\n      <th>Total Achievement towards vaccination to beneficiaries under 2nd Dose of Covishield and Covaxin</th>\n      <th>Total Achievement towards vaccination of Covishield and Covaxin (1st and 2nd Dose)</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>count</th>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.0</td>\n      <td>45.000000</td>\n      <td>...</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.0</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n      <td>45.000000</td>\n    </tr>\n    <tr>\n      <th>mean</th>\n      <td>23.000000</td>\n      <td>45.533333</td>\n      <td>44.955556</td>\n      <td>3.000000</td>\n      <td>1.333333</td>\n      <td>23.044444</td>\n      <td>1.222222</td>\n      <td>417.822222</td>\n      <td>0.0</td>\n      <td>307.511111</td>\n      <td>...</td>\n      <td>4.400000</td>\n      <td>637.155556</td>\n      <td>0.0</td>\n      <td>331.755556</td>\n      <td>55.200000</td>\n      <td>109.933333</td>\n      <td>26.955556</td>\n      <td>1107.222222</td>\n      <td>91.355556</td>\n      <td>1198.577778</td>\n    </tr>\n    <tr>\n      <th>std</th>\n      <td>13.133926</td>\n      <td>28.664676</td>\n      <td>29.017985</td>\n      <td>9.816498</td>\n      <td>3.636932</td>\n      <td>77.816788</td>\n      <td>2.754244</td>\n      <td>493.723344</td>\n      <td>0.0</td>\n      <td>531.891976</td>\n      <td>...</td>\n      <td>9.656369</td>\n      <td>768.935538</td>\n      <td>0.0</td>\n      <td>568.957706</td>\n      <td>80.459363</td>\n      <td>223.154797</td>\n      <td>42.491687</td>\n      <td>1393.188689</td>\n      <td>138.270676</td>\n      <td>1511.056817</td>\n    </tr>\n    <tr>\n      <th>min</th>\n      <td>1.000000</td>\n      <td>2.000000</td>\n      <td>2.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.0</td>\n      <td>0.000000</td>\n      <td>...</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.0</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n    </tr>\n    <tr>\n      <th>25%</th>\n      <td>12.000000</td>\n      <td>24.000000</td>\n      <td>20.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>42.000000</td>\n      <td>0.0</td>\n      <td>35.000000</td>\n      <td>...</td>\n      <td>0.000000</td>\n      <td>129.000000</td>\n      <td>0.0</td>\n      <td>53.000000</td>\n      <td>14.000000</td>\n      <td>7.000000</td>\n      <td>0.000000</td>\n      <td>315.000000</td>\n      <td>19.000000</td>\n      <td>396.000000</td>\n    </tr>\n    <tr>\n      <th>50%</th>\n      <td>23.000000</td>\n      <td>43.000000</td>\n      <td>43.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>0.000000</td>\n      <td>230.000000</td>\n      <td>0.0</td>\n      <td>122.000000</td>\n      <td>...</td>\n      <td>0.000000</td>\n      <td>398.000000</td>\n      <td>0.0</td>\n      <td>124.000000</td>\n      <td>30.000000</td>\n      <td>32.000000</td>\n      <td>8.000000</td>\n      <td>883.000000</td>\n      <td>55.000000</td>\n      <td>883.000000</td>\n    </tr>\n    <tr>\n      <th>75%</th>\n      <td>34.000000</td>\n      <td>61.000000</td>\n      <td>61.000000</td>\n      <td>0.000000</td>\n      <td>1.000000</td>\n      <td>4.000000</td>\n      <td>0.000000</td>\n      <td>585.000000</td>\n      <td>0.0</td>\n      <td>315.000000</td>\n      <td>...</td>\n      <td>4.000000</td>\n      <td>981.000000</td>\n      <td>0.0</td>\n      <td>344.000000</td>\n      <td>63.000000</td>\n      <td>113.000000</td>\n      <td>28.000000</td>\n      <td>1321.000000</td>\n      <td>85.000000</td>\n      <td>1455.000000</td>\n    </tr>\n    <tr>\n      <th>max</th>\n      <td>45.000000</td>\n      <td>105.000000</td>\n      <td>105.000000</td>\n      <td>58.000000</td>\n      <td>20.000000</td>\n      <td>415.000000</td>\n      <td>10.000000</td>\n      <td>2042.000000</td>\n      <td>0.0</td>\n      <td>2828.000000</td>\n      <td>...</td>\n      <td>47.000000</td>\n      <td>3993.000000</td>\n      <td>0.0</td>\n      <td>3007.000000</td>\n      <td>405.000000</td>\n      <td>1263.000000</td>\n      <td>200.000000</td>\n      <td>7179.000000</td>\n      <td>655.000000</td>\n      <td>7834.000000</td>\n    </tr>\n  </tbody>\n</table>\n<p>8 rows × 44 columns</p>\n</div>"},"metadata":{}}]},{"cell_type":"code","source":"data['Session held for Covishield'] = sc1.fit_transform(data[['Session held for Covishield']])","metadata":{"trusted":true},"execution_count":66,"outputs":[]},{"cell_type":"markdown","source":"### Разделяем выборку на тестовую и обучающую","metadata":{}},{"cell_type":"code","source":"X_train, X_test, Y_train, Y_test, X, Y = preprocess_data(data)\nY_test.head()","metadata":{"trusted":true},"execution_count":67,"outputs":[{"execution_count":67,"output_type":"execute_result","data":{"text/plain":"3     0.271845\n2     0.475728\n30    0.116505\n21    0.058252\n22    0.174757\nName: Session held for Covishield, dtype: float64"},"metadata":{}}]},{"cell_type":"code","source":"# Модель линейной регрессии\nLin_Reg = LinearRegression().fit(X_train, Y_train)\n\nlr_y_pred = Lin_Reg.predict(X_test)\n\n\nfig3 = plt.figure(figsize=(7, 5))\nplt.scatter(X_test['Session planned for Covishield_scaled'], Y_test, marker='s', label='Тестовая выборка')\nplt.scatter(X_test['Session planned for Covishield_scaled'], lr_y_pred, marker='o', label='Предсказанные данные')\nplt.legend(loc='lower right')\nplt.xlabel('Session planned for Covishield_scaled')\nplt.ylabel('Session held for Covishield')\nplt.show()\n","metadata":{"trusted":true},"execution_count":68,"outputs":[{"output_type":"display_data","data":{"text/plain":"<Figure size 504x360 with 1 Axes>","image/png":"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\n"},"metadata":{"needs_background":"light"}}]},{"cell_type":"code","source":"# Средняя абсолютная ошибка\nmean_absolute_error(Y_test, lr_y_pred)","metadata":{"trusted":true},"execution_count":69,"outputs":[{"execution_count":69,"output_type":"execute_result","data":{"text/plain":"0.008744568269520277"},"metadata":{}}]},{"cell_type":"code","source":"# Коэффициент детерминации\nr2_score(Y_test, lr_y_pred)","metadata":{"trusted":true},"execution_count":70,"outputs":[{"execution_count":70,"output_type":"execute_result","data":{"text/plain":"0.9987540315739768"},"metadata":{}}]},{"cell_type":"code","source":"# Дерево решений\nclf = tree.DecisionTreeRegressor()\nclf = clf.fit(X_train, Y_train)","metadata":{"trusted":true},"execution_count":71,"outputs":[]},{"cell_type":"code","source":"lr_y_pred = clf.predict(X_test)\n","metadata":{"trusted":true},"execution_count":72,"outputs":[]},{"cell_type":"code","source":"fig5 = plt.figure(figsize=(7, 5))\nplt.scatter(X_test['Session planned for Covishield_scaled'], Y_test, marker='s', label='Тестовая выборка')\nplt.scatter(X_test['Session planned for Covishield_scaled'], lr_y_pred, marker='o', label='Предсказанные данные')\nplt.legend(loc='lower right')\nplt.xlabel('Session planned for Covishield_scaled')\nplt.ylabel('Session held for Covishield')\nplt.show()","metadata":{"trusted":true},"execution_count":73,"outputs":[{"output_type":"display_data","data":{"text/plain":"<Figure size 504x360 with 1 Axes>","image/png":"iVBORw0KGgoAAAANSUhEUgAAAbkAAAE+CAYAAAAQ4W5IAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4xLjMsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+AADFEAAAgAElEQVR4nO3de3gU9dn/8fedEA4qxZ8QrRgVtCgiYB4MeKiKGiu09dBaoVZaxQOKVqk+iofaCtr2elSsVqEWKSKt0iLgCaqiNiJo0Uqw4VwQATVilWClRU5JuH9/zCRuks1mMTvZZPN5XVeu3fnO7Ow9k03u/c7he5u7IyIikomy0h2AiIhIVJTkREQkYynJiYhIxlKSExGRjKUkJyIiGUtJTkREMlabdAewp7p06eLdunVLdxgiItKMLF68uMzdc2u3t7gk161bN4qLi9MdhoiINCNm9l68dh2uFBGRjKUkJyIiGUtJTkREMpaSnIiIZCwlORERyVhKciIikrGU5EREJGMpyYmISMZSkhMRkYwVWZIzsylm9omZLa9nvpnZg2a21syWmlm/qGIREZHWKcqe3FRgcIL53wR6hD9XAL+LMBYREUm3pTPg/t4wdt/gcemMyN8ysiTn7guATxMsci7wRw+8CexrZgdGFY+IiKTR0hkwZxRs+QDw4HHOqMgTXTrPyR0EfBAzXRq2iYhIpim6E8q312wr3x60RyidSc7itHncBc2uMLNiMyvetGlTxGGJiEjKbSnds/YUSWeSKwUOjpnOAzbGW9DdJ7l7gbsX5ObWKRckIiLNXae8PWtPkXQmudnAReFVlscDW9z9ozTGIyIiUSm8HXI61GzL6RC0Ryiyoqlm9mfgVKCLmZUCY4AcAHefCDwPfAtYC2wDLokqFhERSbO+Q4PHojuDQ5Sd8oIEV9UeEXOPexqs2SooKHBVBhcRkVhmttjdC2q3a8QTERHJWEpyIiKSsZTkREQkYynJiYhIxlKSExGRjKUkJyIiGUtJTkREMpaSnIiIZCwlORERyVhKciIikrGU5EREJGMpyYmISMZSkhMRkYylJCciIhlLSU5ERDKWkpyIiGSsyCqDi4iIVDl6zFw+31lZp33vdtmsuGNwZO+rnpyIiEQuXoJL1J4qSnIiIpKxlORERCRjKcmJiEjGUpITEZGMpSQnIiKR27td9h61p4puIRARkchFeZtAIurJiYhIxlKSExGRjKUkJyIiGUtJTkREMpaSnIiIZCwlORERyVhKciIikrGU5EREJGMpyYmISMZSkhMRkYylJCciIhlLSU5ERDKWkpyIiGQsJTkREclYSnIiIpKxlORERCRjKcmJiEjGijTJmdlgM1ttZmvN7JY48zuZ2RwzW2JmK8zskijjERGR1iWyJGdm2cBvgW8CvYAfmFmvWov9GFjp7scApwK/NrO2UcUkIiKtS5Q9uQHAWndf5+67gOnAubWWcaCjmRmwD/ApUBFhTCIi0opEmeQOAj6ImS4N22JNAI4CNgLLgJ+4++4IYxIRkVYkyiRncdq81vQgoAToCuQDE8zsK3VWZHaFmRWbWfGmTZtSH6mIiGSkKJNcKXBwzHQeQY8t1iXAUx5YC6wHetZekbtPcvcCdy/Izc2NLGAREcksUSa5RUAPM+seXkxyATC71jLvA4UAZnYAcCSwLsKYRESkFWkT1YrdvcLMrgFeBLKBKe6+wsxGhvMnAr8ApprZMoLDmze7e1lUMYmISOsSWZIDcPfngedrtU2Meb4RODPKGEREpPWqN8mZ2XjqXihSzd1HRRKRiIhIiiQ6J1cMLAbaA/2Ad8KffKAy+tBEREQap96enLv/AcDMhgOnuXt5OD0ReKlJohMREWmEZK6u7Ap0jJneJ2wTERFp1pK58OQu4B9mNi+cHgiMjSwiERGRFGkwybn7o2b2AnBc2HSLu/8r2rBEREQaL9HVlf1qNVWNQ9nVzLq6+9vRhSUiItJ4iXpyv04wz4HTUxyLiIhISiW6uvK0pgxEREQk1Rq8utLM9jKzn5nZpHC6h5mdFX1oIiIijZPMLQSPAruAE8PpUuCXkUUkIiKSIskkucPd/R6gHMDdtxO/VpyIiEizkkyS22VmHQjHsTSzw4GdkUYlIiKSAsncDD4GmAscbGbTgK8Dw6MMSkREJBWSuRn8ZTN7Gzie4DDlT1TzTUREWoJ6D1eaWc/wsR9wKPARsBE4JM6N4iIiIs1Oop7c/wJXEP+mcN0MLiIizV6im8GvCB91U7iIiLRIyVx4gpmdCHSLXd7d/xhRTCIiIinRYJIzs8eAw4ESvqgI7oCSnIiINGvJ9OQKgF7u7lEHIyIikkrJ3Ay+HPhq1IGIiIikWqJ6cnMIDkt2BFaa2VvEjHTi7udEH56IiMiXl+hw5b1NFoWIiEgEEt1CMB/AzPYGtrv7bjM7AugJvNBE8YmIpMTRY+by+c7KOu17t8tmxR2D0xCRNIVkzsktANqb2UFAEXAJMDXKoEREUi1egkvULpkhmSRn7r4NOA8Y7+7fBY6ONiwREZHGSyrJmdkJwDDgubAtO7qQREREUiOZJHcdcCvwtLuvMLPDgHnRhiUiItJ4yZTamQ/Mj5leB4yKMigRkSick/U6N7WZQVcrY6N34Z6KoczefVK6w5IIJbpP7jfufl3M/XI16D45EWlJhrRbyB1MZi/bBUCelXFXzmTakQV8O73BSWQS9eQeCx91v5yItHjj9n0Wtuyq0baX7WJcp2eBX6UnKIlcovvkFodP9wOed/ed9S0rItLsbSnds3bJCMlceHIOsMbMHjOzb5tZUuV5RESalU55e9YuGaHBJOfulwBfA2YCFwLvmtnkqAMTEUmpwtshp0PNtpwOQbtkrKR6Ze5ebmYvEFyA0gE4F7g8ysBERFKq79DgsejO4BBlp7wgwVW1S0ZKpmjqYOAC4DTgVWAyoE+FiLQ8fYcqqbUyyfTkhgPTgSt18YmIiLQkydwMfoGZHQB8w8wA3nL3TyKPTEREpJEavPDEzIYAbwFDCA5T/t3Mzo86MBERkcZK5nDlz4D+Vb03M8sF/grMijIwERGRxkrmPrmsWocnNyf5OsxssJmtNrO1ZnZLPcucamYlZrbCzObHW0ZEROTLSKYnN9fMXgT+HE5/nyQqg5tZNvBb4BtAKbDIzGa7+8qYZfYFHgIGu/v7Zrb/nm6AiIhIfZK58GS0mZ0HnAQYMMndn05i3QOAtWHVAsxsOsH9dStjlrkQeMrd3w/fSxe0iIhIytR72NHMvmZmXwdw96fc/X/d/Xpgs5kdnsS6DwI+iJkuDdtiHQH8PzN71cwWm9lFexi/iIhIvRKdW/sN8N847dvCeQ2xOG21S/a0AY4lqHMxCPi5mR1RZ0VmV5hZsZkVb9q0KYm3FhERSZzkurn70tqN7l4MdEti3aXAwTHTecDGOMvMdffP3b0MWAAcE+c9J7l7gbsX5ObmJvHWIiIiiZNc+wTzOiSYV2UR0MPMuptZW4KhwWbXWuZZ4GQza2NmewHHAauSWLeIiEiDEiW5RWY2onajmV0GLI6zfA3uXgFcA7xIkLhmuPsKMxtpZiPDZVYBc4GlBDecT3b35Xu+GSIiInWZe+3TZOGMYCivp4FdfJHUCoC2wHfd/V9NEmEtBQUFXlxcnI63FhGRZsrMFrt7Qe32RJXBPwZONLPTgN5h83Pu/kpEMYqIiKRUMvfJzQPmNUEsIiIiKZXU8FwiIiItkZKciIhkrIRJzsyyzeyvTRWMiIhIKiVMcu5eCWwzs05NFI+IiEjKJFOFYAewzMxeBj6vanT3UZFFJSIikgLJJLnnwh8REZEWJZlbCP4QDstVNXDyancvjzYsERGRxmswyZnZqcAfgA0ElQUONrOL3X1BtKGJiIg0TjKHK38NnOnuqwHCUjh/JiiRIyIi0mwlc59cTlWCA3D3NUBOdCGJiIikRjI9uWIzewR4LJweRhJVCERERNItmSR3FfBjYBTBObkFwENRBiUiIpIK9SY5Myty90LgTne/Gbiv6cISERFpvEQ9uQPNbCBwjplNJ+jFVXP3tyONTEREpJESJbnbgVuAPOr24hw4PaqgREREUiFR0dRZwCwz+7m7/6IJYxIREUmJBm8hUIITEZGWSvXkREQkYynJiYhIxkp0C8F+iV7o7p+mPhwREZHUSXR15WKCqygNOAT4d/h8X+B9oHvk0YmIiDRCoqsruwOY2URgtrs/H05/EzijacITEYCjx8zl852Vddr3bpfNijsGpyEikZYhmXNy/asSHIC7vwAMjC4kEaktXoJL1C4igWTGriwzs58BjxMcvvwhsDnSqERERFIgmZ7cD4Bc4GngGWD/sE1ERKRZa7AnF15F+ZMmiEVERCSlEt1CMIfg8GRc7n5OJBGJSFznZL3OTW1m0NXK2OhduKdiKLN3n5TusESatUQ9uXubLAoRSWhIu4XcwWT2sl0A5FkZd+VMph1ZwLfTG5xIM5boFoL5Vc/NrANwiLuvbpKoRKSGcfs+C1t21Wjby3YxrtOzwK/SE5RIC9DghSdmdjZQAswNp/PNbHbUgYlIjC2le9YuIkByV1eOBQYAnwG4ewnQLbqQRKSOTnl71i4iQHJJrsLdt0QeiYjUr/B2yOlQsy2nQ9AuIvVKJsktN7MLgWwz62Fm44GFEcclIrH6DoWzH4ROBwMWPJ79YNAuIvVKZsSTa4HbgJ3An4EXARVSFWlqfYcqqYnsoWRuBt9GkORuiz4cERGR1GkwyZnZEcCNBBebVC/v7qdHF5aIiEjjJXO4ciYwEZgMaMhzERFpMZJJchXu/rvIIxEREUmxRGNX7hc+nWNmVxNUIdhZNT8cuFlERKTZStSTW0wwQLOF06Nj5jlwWEMrN7PBwANANjDZ3e+qZ7n+wJvA9919VhJxi4iINCjR2JXdG7NiM8sGfgt8AygFFpnZbHdfGWe5uwluTRAREUmZZG4G/7IGAGvdfZ277wKmA+fGWe5a4EngkwhjERGRVijKJHcQ8EHMdGnYVs3MDgK+S3D1poiISEpFmeQsTlvtIqy/AW5294S3JpjZFWZWbGbFmzZtSlmAIiKS2ZK5haCqx3UoNW8GX9DAy0qBg2Om84CNtZYpAKabGUAX4FtmVuHuz8Qu5O6TgEkABQUF9VYrFxERiZXMiCd3A98HVvLFzeAONJTkFgE9zKw78CFwAXBh7AKxF7eY2VTgL7UTnEhTOHrMXArL53NTmxl0tTI2ehfuqRhKUc5AVtwxON3hiciXlExP7jvAke6+s8ElY7h7hZldQ3DVZDYwxd1XmNnIcL7Ow0mzUVg+n7tyJrOXBdW386yMu3Imc0s5gJKcSEuVTJJbB+QQcyN4stz9eeD5Wm1xk5u7D9/T9Yukyk1tZlQnuCp72S5uajMD+L/0BCUijZZMktsGlJhZETVHPBkVWVQiTayrldXTvrmJIxGRVEomyc0Of0Qy1kbvQl6cRLfRO5OXhnhEJDUavIXA3f9AUCx1cfjzp7BNJGPcUzGUbd62Rts2b8s9FSpSKtKSNZjkzOxU4B2CIboeAtaY2SkRxyXSpIpyBnJL+eWU7u7CbjdKd3fhlvLLKcoZmO7QRKQRzD3xbWdmthi40N1Xh9NHAH9292ObIL46CgoKvLi4OB1vLSIizZSZLXb3gtrtyYx4klOV4ADcfQ3B1ZYiIiLNWjIXnhSb2SPAY+H0MIJzcyIiIs1aMknuKuDHwCiC8SgXEJybExERadYaTHLhSCf3hT8iIiItRr1JzsxmuPtQM1tG3eoBuHvfSCMTERFppEQ9uZ+Ej2c1RSAiIiKpVu/Vle7+Ufi0DPjA3d8D2gHHULdkjoiISLOTzC0EC4D2YU25IuASYGqUQYmIiKRCMknO3H0bcB4w3t2/C/SKNiwREZHGSyrJmdkJBPfHPRe2JVVRXEREJJ2SSXLXAbcCT4dFTw8D5kUbloiISOMlc5/cfGA+gJllAWWqJSciIi1BMlUI/mRmXzGzvYGVwGozGx19aCIiIo2TzOHKXu7+H+A7wPPAIcCPIo1KREQkBZKqQmBmOQRJ7ll3LyfOCCgiIiLNTTJJ7mFgA7A3sMDMDgX+E2VQIiIiqZDMhScPAg/GNL1nZqdFF5KIiEhqJHPhyQFm9oiZvRBO9wIujjwyERGRRkrmpu6pwKPAbeH0GuAJ4JGIYpIMcPSYuRSWz+emNjPoamVs9C7cUzGUopyBrLhjcLrDE5FWIplzcl3cfQawG8DdK4DKSKOSFq+wfD535UwmL6uMLIO8rDLuyplMYfn8dIcmIq1IMknuczPrTHhFpZkdD2yJNCpp8W5qM4O9bFeNtr1sFze1mZGmiESkNUrmcOX/ArOBw83sb0AucH6kUUmL19XK6mnf3MSRiEhrlszVlW+b2UDgSMCA1eG9ciL12uhdyIuT6DZ6Z/LSEI+ItE71Hq40s/5m9lWoPg93LPAr4Ndmtl8TxSct1D0VQ9nmbWu0bfO23FMxNE0RiUhrlOic3MPALgAzOwW4C/gjwfm4SdGHJi1ZUc5Abim/nNLdXdjtRunuLtxSfjlFOQPTHZqItCLmHn+ELjNb4u7HhM9/C2xy97HhdIm75zdZlDEKCgq8uLg4HW8tIiLNlJktdveC2u2JenLZZlZ1zq4QeCVmnoqmiohIs5coWf0ZmG9mZcB24DUAM/sauoVARERagHqTnLv/ysyKgAOBl/yL45pZwLVNEZyIiEhjJDzs6O5vxmlbE104IiIiqZPMiCciIiItkpKciIhkLCU5ERHJWEpyIiKSsZTkREQkY0Wa5MxssJmtNrO1ZnZLnPnDzGxp+LPQzI6JMh4REWldIktyZpYN/Bb4JtAL+IGZ9aq12HpgoLv3BX6BxsQUEZEUirInNwBY6+7r3H0XMB04N3YBd1/o7v8OJ98EVWEREZHUiTLJHQR8EDNdGrbV5zLghQjjERGRVibKgZYtTlvckgdmdhpBkjupnvlXAFcAHHLIIamKT0REMlyUPblS4OCY6TxgY+2FzKwvMBk41903x1uRu09y9wJ3L8jNzY0kWBERyTxRJrlFQA8z625mbYELgNmxC5jZIcBTwI80JqaIiKRaZIcr3b3CzK4BXgSygSnuvsLMRobzJwK3A52Bh8wMoCJe0TsREZEvo97K4M2VKoMHut3yHHe0mcKw7FfIZjeVZDGt8nTGVFzKhru+ne7wRESaVH2VwVXhu4W6o80ULsr+KxZe3tOG3VyU/ddwrpKciAhoWK8Wa1j2K9UJropZ0C4iIgEluRYqm9171C4i0hopybVQlfX86uprFxFpjfQfsYWaVnk6ta8Zcg/aRUQkoCTXQo2puJQ/Vp5BhWfhDhWexR8rz2BMxaXpDk1EpNnQLQQiItLi1XcLgXpyIiKSsZTkREQkYynJiYhIxlKSExGRjKUkJyIiGUtJTkREMpYGaI7I0WPm8vnOyjrte7fLZsUdg9MQkYhI66OeXETiJbhE7SIiknrqyYlI0srLyyktLWXHjh3pDkVaqfbt25OXl0dOTk5SyyvJiUjSSktL6dixI926dcNq13oSiZi7s3nzZkpLS+nevXtSr9HhShFJ2o4dO+jcubMSnKSFmdG5c+c9OpKgJBehc7Je5/W2o1jX7kJebzuKc7JeT3dIIo2mBCfptKefPx2ujMiQdgu5g8nsZbsAyLMy7sqZTDuygG+nNziRFmrz5s0UFhYC8K9//Yvs7Gxyc3MBeOutt2jbtm06w2sSlZWV/PrXv+aZZ55hx44dXHXVVYwYMSLdYTVbSnIRGbfvs7BlV422vWwX4zo9C/wqPUGJtHCdO3empKQEgLFjx7LPPvtw4403pjmqpjV27FiysrIoKiqiQ4cO6Q6n2dPhyqhsKd2zdpEMc/SYuXS75bk6P0ePmRvJ+z3++OMMGDCA/Px8rrzySiorg9t15s6dS79+/TjmmGMoLCxk+/bt5Ofnk5+fT9u2benTpw/5+fkUFxfz3nvvUVhYSN++fSksLOT9998HYPjw4XTv3p3evXvTt29fli9fDsDvf/97+vfvzzHHHMP3vvc9tm3bBsC7775bHUv37t0ZPnx4nXjHjh3LQQcdRN++fenZsyevvPJK9XvNmjWrxrL33nsvY8eOBWDatGm89tprDBgwoEaMiWIfOXIkJ598MkcccQR/+ctfAJg6dSrXXHMNANOnT2fQoEGUl5ezYcMGTj75ZPr160e/fv1YuHBhqn5FaaEkF5VOeXvWLpJhmvJe0VWrVvHEE0/wt7/9jZKSErKzs5k2bRqbNm1ixIgRPPnkkyxZsoSZM2fSoUMHSkpKKCkpoWvXrsybN4+SkhIKCgq45ppruOiii1i6dCnDhg1j1KhR1e8xbtw4li9fzimnnFKdkM477zwWLVrEkiVLOOqoo3jkkUcAeOihhxg6dCglJSWMGzeu3rivv/56li5dymWXXVadfBqyfv16Lr74YpYtW1YjxkSxb9iwgfnz5/Pcc88xcuTIGhduFBUV8cADDzBr1ixycnLYf//9efnll3n77bd54oknaqynJVKSi0rh7ZBT61BCToegXURSqqioiMWLF9O/f3/y8/MpKipi3bp1vPnmm5xyyinVl5vvt99+CdfzxhtvcOGFFwLwox/9iNdf/+JisdGjR9OjRw9mz57NkCFDAFi+fDknn3wyffr0Ydq0aaxYsQKA7Oxs/vvf/zYY9/3330+vXr24++67ueSSS2q8V35+PoWFhaxZs6bGa7KysuLGmCj2oUOHkpWVRY8ePTjssMP45z//CcCyZcv47ne/y0033UTHjh2B4F7IESNG0KdPH4YMGcLKlSsb3I7mTEkuKn2HwtkPQqeDAQsez34waBeRlHJ3Lr744uoe2urVqxk7dizu3qirQWNfO27cON555x1uv/12xowZAwSHAidMmMCyZcsYM2ZMdQ/puuuu4+WXX+aQQw5h9OjR9a7/+uuvZ+XKlUyfPp0bbrihxnuVlJTwgx/8oPowZZWqZBQvxvraay9TNb1q1Sr+9Kc/1Yj9/vvv54ADDmDJkiUUFxeza1fNawtaGiW5KPUdCtcvh7GfBY9KcCKRKCwsZNasWXzyyScAfPrpp7z33nuccMIJzJ8/n/Xr11e3J3LiiScyffp0IDj3ddJJJ9VZ5itf+QplZWUA/Pe//+XAAw+kvLycadOmVS/TuXNncnJyeO655xIeroy3zlidO3euk2T69+8fN8ZEsc+cOZPdu3fz7rvvsm7dOo488kgg6OGdddZZnH/++dx5550AbNmyhQMPPJCsrCwee+yx6nObLZWurhSRFq9Xr1788pe/5Mwzz2T37t3k5OTw29/+luOPP55JkyZx3nnnsXv37urzTfV58MEHufTSSxk3bhy5ubk8+uij1fNGjx7NL3/5S8yMyZMnA/CLX/yC4447jkMPPZQ+ffpUH6K8/vrrGT58OH369GH16tX1vt/999/P448/TkVFBffee291+89//nN+85vfsHPnTh5++OHqc4AAEyZM4LLLLmPcuHHsv//+TJkypcHYjzzySAYOHMjHH3/MxIkTad++fY04br31VgYMGMAFF1zA1Vdfzfe+9z1mzpzJaaedxt57753Mr6DZMndPdwx7pKCgwIuLi9MdhkirtGrVKo466qikllUljuZh+PDh1b21TBHvc2hmi929oPayrbYnpz9AkWjp70iag1ab5FQKR0Rag6lTp6Y7hLTShSciIpKxlORERCRjKcmJiEjGUpITEZGM1WovPNm7XXa9V1eKSPOVnZ1Nnz59qqc//fRTzjnnHCZMmJDGqKS5arVJbsUdg2HpDCi6M6gM0CkvGFdSo5KINGtVAyxXmTp1Krp3VurTeg9XLp0Bc0bBlg8ADx7njAraRSQ1ls6A+3vD2H2Dx4j/vuorK1NZWcno0aPp378/ffv25eGHH65+TXFxMfvssw/5+fkccsgh1eVnKisrufHGG+nTpw99+/Zl/PjxAHTr1o2ysjK2bt3K17/+dV566SUA7rzzTvr370/v3r254oorqBpo49prr6Vfv3707NmTn/3sZwD1lrN59dVXOeuss6pjiy2xc+qpp9ZI5vvss0/c1wCUlZXRrVu3Bre99mvatm1Lfn4+X/va16rXuXXrVgoLC+nXrx99+vTh2Wefrd6G3r17V79+1qxZ1SWFapcL6t27Nxs2bKjzmtrbAsG4nVWxVo0R2hitN8kV3Qnl22u2lW8P2kWk8dL0RTJeWZlHHnmETp06sWjRIhYtWsTvf//76vEsKysrGTBgACUlJdXjNwJMmjSJ9evX849//KO6fE2V8vJyhgwZwlVXXcWZZ54JBKVuFi1axPLly9m+fXt1gh0/fjxvv/02b7zxBg888AA7duxo0nI2ibY9VmVlJXl5eZSUlFQPWwbQvn17nn76ad5++23mzZvHDTfcQFQjZb300ku88847vPXWW5SUlLB48WIWLFjQqHW22sOVKmoqErFEXyQjPC0Qr6zMSy+9xNKlS6t7F1u2bOGdd96he/fubN26NW4Jnr/+9a+MHDmSNm2Cf5Oxy4wYMYKPPvqIH/7wh9Vt8+bN45577mHbtm18+umnHH300Zx99tkAnH322RQVFTF69Gjat2/Pli1buOaaa6pr38WW03nttdfIz88HqK6HV2XYsGHV1cC3b99e5zVmxrXXXss555xTPS/Rtseqbz+4Oz/96U9ZsGABWVlZfPjhh3z88cdAUBy2KtYtW7YwcODA6tdVjfVZtVyV2NcMGTKE2267rUasL730Ev/zP/9THdM777zDKaecUieuZLXeJNcpL/yGGaddRBovTV8k45WVcXfGjx/PoEGD6iy/fv168vLq/t0nKtPTo0cPOnfuzJQpU7j00kvZsWMHV199NcXFxRx88MGMHTu2RmHSOXPmsHnzZgYNGsQNN9xQo5zN7t27awyYfPLJJ1f3Au+99162bt1aPW/atGkUFATDM8Ye4qt6TVlZGT179uSMM86osR31bXsy+6Gq+OzixYvJycmhW7du1dt2+OGHV58fnTVrVo3Cr+PGjaseLzP2EGXVa7Zt20Z+fn6NMTXdnVtvvZUrr7wyYax7ovUerlRRU5Fo1feFMeIvkvHKygwaNIjf/aabYoQAAA2xSURBVO53lJeXA7BmzRo+//xz3J0nn3yyzjktgDPPPJOJEydSUVEB1CzTc9ttt3Hfffdxzz338PHHH1f/0+/SpQtbt26tcT7qs88+AyAnJ4ePP/6YzZs3R1bOpmPHjrRp06bG+urb9tpmzpwZdz9s2bKF/fffn5ycHObNm8d7772Xklg7dOjAXnvtVR1XVaxTpkypTuwffvhhdfmkLyvSnpyZDQYeALKBye5+V635Fs7/FrANGO7ub0cZU7WqwyW6ulIkGoW3B+fgYg9ZNsEXyXhlZS6//HI2bNhAv379cHdyc3N55plnuPnmm5k7dy4ffvghWVlZfPrpp2zfvp3hw4dz+eWXs2bNGvr27UtOTg4jRoyovigFglpvt99+O9deey0zZsyorqbdrVs3+vfvX73ckCFD+OSTT9i2bRuXXXYZ3bt3T3k5m4ULF3LSSSfx+eefc/3119corFrftsd66KGHmDRpEvPnz2fChAls3bqVTZs2MXv2bIYNG8bZZ59NQUEB+fn59OzZs1Gxrl+/npNOOont27dzyimn1OjlnXnmmaxatYoTTjgBCHqrjz/+OPvvv/+Xf0N3j+SHILG9CxwGtAWWAL1qLfMt4AXAgOOBvze03mOPPdZFJD1Wrly5Zy9Y8oT7fUe7j+kUPC55IprAQhdffLHPnDlzj5Zfv359jbbx48f7vHnzUhtYMzdmzJg62zxnzhx/9NFH0xJPQ+J9DoFij5MzouzJDQDWuvs6ADObDpwLrIxZ5lzgj2GAb5rZvmZ2oLt/FGFcItJU+g5t1kdHrrrqKnJzc2u0DRo0iE6dOqUpovQ4//zz6/SW+vXrx86dO9MUUepEmeQOAmKv7CgFjktimYMAJTkR2WN7WlbmuONq/0sKLippbeLdu9a1a9c0RJJ6UV54Eu+ypNo3VySzDGZ2hZkVm1nxpk2bUhKciIhkviiTXClwcMx0HrDxSyyDu09y9wJ3L6h9aEFEmpZHdCOwSDL29PMXZZJbBPQws+5m1ha4AJhda5nZwEUWOB7YovNxIs1X+/bt2bx5sxKdpIW7s3nz5hr3FTYksnNy7l5hZtcALxJcaTnF3VeY2chw/kTgeYIrLNcS3EJwSVTxiEjj5eXlUVpaik4bSLq0b98+7k3r9bGW9o2soKDANeK4iIjEMrPF7l5Qu731jngiIiIZT0lOREQylpKciIhkrBZ3Ts7MNgGpGSG0deoClKU7iAyg/Zg62pep0dr346HuXucesxaX5KRxzKw43slZ2TPaj6mjfZka2o/x6XCliIhkLCU5ERHJWEpyrc+kdAeQIbQfU0f7MjW0H+PQOTkREclY6smJiEjGUpLLQGY22MxWm9laM7slzvxhZrY0/FloZsekI86WoKF9GbNcfzOrNLPzmzK+liKZ/Whmp5pZiZmtMLP5TR1jS5HE33cnM5tjZkvCfdmqxwTW4coMY2bZwBrgGwSljBYBP3D3lTHLnAiscvd/m9k3gbHuXrd6ZCuXzL6MWe5lYAfBQOSzmjrW5izJz+S+wEJgsLu/b2b7u/snaQm4GUtyX/4U6OTuN5tZLrAa+Kq770pHzOmmnlzmGQCsdfd14Yd6OnBu7ALuvtDd/x1OvklQx0/qanBfhq4FngT0Tzm+ZPbjhcBT7v4+gBJcvZLZlw50NDMD9gE+BSqaNszmQ0ku8xwEfBAzXRq21ecy4IVII2q5GtyXZnYQ8F1gYhPG1dIk85k8Avh/ZvaqmS02s4uaLLqWJZl9OQE4iqAA9TLgJ+6+u2nCa34iqycnaWNx2uIekzaz0wiS3EmRRtRyJbMvfwPc7O6VwRdniSOZ/dgGOBYoBDoAb5jZm+6+JurgWphk9uUgoAQ4HTgceNnMXnP3/0QdXHOkJJd5SoGDY6bzCL7R1WBmfYHJwDfdfXMTxdbSJLMvC4DpYYLrAnzLzCrc/ZmmCbFFSGY/lgJl7v458LmZLQCOITj/JF9IZl9eAtzlwQUXa81sPdATeKtpQmxedLgy8ywCephZdzNrC1wAzI5dwMwOAZ4CfqRvygk1uC/dvbu7d3P3bsAs4GoluDoa3I/As8DJZtbGzPYCjgNWNXGcLUEy+/J9gh4xZnYAcCSwrkmjbEbUk8sw7l5hZtcALwLZBFf7rTCzkeH8icDtQGfgobAHUqGBXetKcl9KA5LZj+6+yszmAkuB3cBkd1+evqibpyQ/k78ApprZMoLDmze7e6utTqBbCEREJGPpcKWIiGQsJTkREclYSnIiIpKxlORERCRjKcmJiEjGUpITEZGMpSQnjWZmt4UlPZaGpVJSUtHAzLqaWaQj+pvZWDO7Mcr3SPDe3cws7r1gZjYu3KfjGrH+AWa2ICzL8k8zmxzeaL2n6xmZaCzJRPvQzBYmsf6t9bRPjbp0kZltMLMue7D8cDObEGVMklq6GVwaxcxOAM4C+rn7zvAfRttUrNvdNwKttT7blUCuu+9MZmEza+PuFTHTBwAzgQvc/Y1wRPrvAR2BbXsSSGNuenf3E7/sa0VSQT05aawDCcYc3Ang7mVhcsLMjjWz+eGo8i+a2YFh+ygzWxn2/KaHbQPDXmCJmf3DzDrG9nTMrL2ZPWpmy8L5p4Xtw83sKTOba2bvmNk98YIMv7HfbWZvhT9fi7PMCDNbFBabfLKq1xP2KB60oMDsuqrehQVFPl81s1lhT2lamEwSbfux4frfAH5cT6yzgb2Bv5vZ983sUDMrCvdXUTgsW1Vc95nZPODuWqv5MfAHd38j/L24u89y94/NbD8zeyZc35tm1tfMssJ9tG9MHGvN7IDYnlq8312oV7gv1pnZqJh1bI15Pjrcv0vN7I44221mNiFc/3PA/vH2T8zyd8XEcm/YdoCZPR3u4yUW1E4k3N7FFvSOr6hnfT8MPxslZvawBbXbMLNLzGyNBYVcv54oJmmG3F0/+vnSPwT1qkoIBtJ9CBgYtucQFMHMDae/TzAEEQQDyrYLn+8bPs4Bvh6zzjZAN2B52HYD8Gj4vCfB+HztgeEE4/J1CqffAw6OE+cG4Lbw+UXAX8LnY4Ebw+edY5b/JXBt+HwqQa8oC+hFUM8L4FRgC8EguVnAGwQVHRJt+9KYfTSuavvixLs15vkc4OLw+aXAMzFx/QXIjvP6p4Bz61n3eGBM+Px0oCR8/gBwSfj8OOCvcfZRvN/d2HB72xEMUr0ZyIndDuBMYBLBMFNZYdyn1FrmPILis9lAV+Az4Px6tmE/gmKgViuWJ4DrwufZBMVDAfYLHzsAy6t+1+HnogtBaZo5MXE/FH5ODiT4rOUSHKH4GzAh3X93+kn+Rz05aRR330pQIuUKYBPwhJkNJxgUtjdBmY8S4Gd8UZx1KTDNzH7IF8Uc/wbcF/YC9vWYQ2+hk4DHwvf8J0EyOyKcV+TuW9x9B7ASOLSecP8c83hCnPm9zew1C8b8GwYcHTPvGXff7UEF5gNi2t9y91IP6nWVECTmuNtuZp3CbZsfvvaxeuKs7QTgTzGviS2NNNPdK5NcT5XYffkK0DmM7QmChAzBwL9PxHltvN8dwHPuvtODMRI/oeY+giDJnQn8A3ib4ItKj1rLnAL82d0rPTga8EqCbfgPQSX2yWZ2Hl8cgj0d+F24bZXuviVsH2VmSwiKBB8c570LCT7Hi8LfWSFwGEGyf9XdN3lQpDTePpFmTOfkpNHCf7KvAq+GCeJiYDGwwt3jJZNvE/xDOwf4uZkd7e53hYeovgW8aWZnEPwTq5KoWFvseatK6v9cez3Pq0wFvuPuS8JEfWo972H1tFe9txFn28NDgakYLDZ2HZ/Xs8wKgn/az8aZV19NsjeAr5lZLvAdgt5sbXV+d2F7Q78DA/7P3R+uJ97YOBrkwUDFAwiS0QXANQQJrg4zOxU4AzjB3beZ2asEvf7a8f3B3W+t9drvJBuTNE/qyUmjmNmRZhb7rTifoJe1Gsi14MIUzCzHzI42syyCw4nzgJuAfYF9zOxwd1/m7ncDxQTf9GMtIOhdYWZHAIeE77Envh/z+Eac+R2Bj8wsp+q9vqS42+7unwFbzKyqJ5bseywk+Ede9ZrXk3jNBOBii7nSNTzn9FVq7stTCc6p/sfdHXgauA9Y5bXqDNb3u0tyG14ELjWzfcJ1HWRmtc+5LQAuMLPs8BzmafWtLFxPJ3d/HriO4HMHUARcFS6TbWZfITiU/e8wwfUEjo+zyiLg/KqYwvOWhwJ/B041s87h52JIktsrzYR6ctJY+wDjw15KBbAWuMLdd1lwgcaD4aGwNgRVtNcAj4dtBtzv7p+Z2S8suJikkuCQ4wsE50OqPARMDHuKFcBwD67m3JNY25nZ3wm+3P0gzvyfE/xTew9YRpD09liCbV9BUNByipltI/jHn4xR4WtGExwSviSJGD42swuAe8N/3LsJkshTBOfQHjWzpQSH+S6OeekTBDXLhsdZbTbxf3cNboC7v2RmRxFU/AbYCvyQ4NBmlacJemPLCD4n82uvJ0ZH4Fkzax/Gcn3Y/hNgkpldRvBZugqYC4wMt3c1wSHL2vGtNLOfAS+Fybwc+LG7v2lmYwm+FH1EcKg1u8ENlmZDpXakVTCzDUCBt+K6WiKtkQ5XiohIxlJPTkSaNTN7Guheq/lmd0/2cK+0YkpyIiKSsXS4UkREMpaSnIiIZCwlORERyVhKciIikrGU5EREJGP9fyOUcq+73ba9AAAAAElFTkSuQmCC\n"},"metadata":{"needs_background":"light"}}]},{"cell_type":"code","source":"# Средняя абсолютная ошибка\nmean_absolute_error(Y_test, lr_y_pred)","metadata":{"trusted":true},"execution_count":74,"outputs":[{"execution_count":74,"output_type":"execute_result","data":{"text/plain":"0.020496224379719534"},"metadata":{}}]},{"cell_type":"code","source":"# Коэффициент детерминации\nr2_score(Y_test, lr_y_pred)","metadata":{"trusted":true},"execution_count":75,"outputs":[{"execution_count":75,"output_type":"execute_result","data":{"text/plain":"0.9819319086806477"},"metadata":{}}]},{"cell_type":"code","source":"from sklearn.svm import SVR\nsvr_1 = SVR()\nsvr_1.fit(X_train, Y_train)","metadata":{"trusted":true},"execution_count":76,"outputs":[{"name":"stderr","text":"/srv/conda/envs/notebook/lib/python3.7/site-packages/sklearn/svm/base.py:193: FutureWarning: The default value of gamma will change from 'auto' to 'scale' in version 0.22 to account better for unscaled features. Set gamma explicitly to 'auto' or 'scale' to avoid this warning.\n  \"avoid this warning.\", FutureWarning)\n","output_type":"stream"},{"execution_count":76,"output_type":"execute_result","data":{"text/plain":"SVR(C=1.0, cache_size=200, coef0=0.0, degree=3, epsilon=0.1,\n    gamma='auto_deprecated', kernel='rbf', max_iter=-1, shrinking=True,\n    tol=0.001, verbose=False)"},"metadata":{}}]},{"cell_type":"code","source":"y_pred_1 = svr_1.predict(X_test)","metadata":{"trusted":true},"execution_count":77,"outputs":[]},{"cell_type":"code","source":"fig5 = plt.figure(figsize=(7, 5))\nplt.scatter(X_test['Session planned for Covishield_scaled'], Y_test, marker='s', label='Тестовая выборка')\nplt.scatter(X_test['Session planned for Covishield_scaled'], y_pred_1, marker='o', label='Предсказанные данные')\nplt.legend(loc='lower right')\nplt.xlabel('Session planned for Covishield_scaled')\nplt.ylabel('Session held for Covishield')\nplt.show()","metadata":{"trusted":true},"execution_count":78,"outputs":[{"output_type":"display_data","data":{"text/plain":"<Figure size 504x360 with 1 Axes>","image/png":"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\n"},"metadata":{"needs_background":"light"}}]},{"cell_type":"code","source":"mean_absolute_error(Y_test, y_pred_1), mean_squared_error(Y_test, y_pred_1)","metadata":{"trusted":true},"execution_count":79,"outputs":[{"execution_count":79,"output_type":"execute_result","data":{"text/plain":"(0.061233184940736596, 0.004694654998016561)"},"metadata":{}}]},{"cell_type":"code","source":"","metadata":{},"execution_count":null,"outputs":[]}]}